Brokers Offer Predictions for Theravance Biopharma’s FY2019 Earnings (TBPH)

Theravance Biopharma (NASDAQ:TBPH) – Investment analysts at Cantor Fitzgerald issued their FY2019 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Tuesday, May 22nd. Cantor Fitzgerald analyst L. Chen anticipates that the biopharmaceutical company will earn ($3.74) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $55.00 price target on the stock.

Get Theravance Biopharma alerts:

A number of other research firms also recently commented on TBPH. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Leerink Swann increased their target price on Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. BidaskClub upgraded Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research note on Friday, February 9th. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a research note on Wednesday, May 9th. Finally, Zacks Investment Research lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. Four equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $39.29.

Theravance Biopharma stock opened at $23.70 on Thursday. The stock has a market capitalization of $1.26 billion, a PE ratio of -4.35 and a beta of 1.81. The company has a current ratio of 4.25, a quick ratio of 4.08 and a debt-to-equity ratio of 3.53. Theravance Biopharma has a 12 month low of $21.27 and a 12 month high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.26) by $0.04. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. The business had revenue of $8.32 million for the quarter, compared to the consensus estimate of $5.74 million.

In other news, CFO Renee D. Gala sold 10,000 shares of Theravance Biopharma stock in a transaction on Friday, May 18th. The stock was sold at an average price of $24.29, for a total transaction of $242,900.00. Following the transaction, the chief financial officer now directly owns 236,022 shares in the company, valued at approximately $5,732,974.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.10% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. UBS Group AG grew its holdings in shares of Theravance Biopharma by 88.4% in the 1st quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 2,117 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Theravance Biopharma by 22.3% during the first quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 3,042 shares in the last quarter. Swiss National Bank grew its holdings in shares of Theravance Biopharma by 5.3% during the first quarter. Swiss National Bank now owns 75,142 shares of the biopharmaceutical company’s stock valued at $1,822,000 after buying an additional 3,800 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Theravance Biopharma by 0.9% during the first quarter. Northern Trust Corp now owns 516,551 shares of the biopharmaceutical company’s stock valued at $12,526,000 after buying an additional 4,509 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Theravance Biopharma during the first quarter valued at $130,000. Institutional investors own 85.94% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Leave a Reply

Your email address will not be published. Required fields are marked *